Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1413 participants.

Also called NCT01719003

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,413 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01719003
  • EudraCT 2010-021375-92
Other papers using this trial's data
  • Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes Diabetes care, 2016-10 DOI, PubMed 27493136

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Brazil, Canada, Czechia, Egypt, France, Germany, Guatemala, Lebanon, Malaysia, Mexico, Peru, Philippines, Russia, Serbia, South Korea, Spain, Taiwan, Thailand, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01719003. Randomized; double masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2016-02-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Condition
Hyperglycemia
Intervention (Drug)
Metformin 500 mg bid
Intervention (Drug)
Metformin 1000 mg bid
Intervention (Drug)
Empagliflozin low dose qd
Intervention (Drug)
Empagliflozin high dose qd
Intervention (Drug)
Empagliflozin low dose bid
Intervention (Drug)
Metformin 500 mg bid
Intervention (Drug)
Empagliflozin high dose bid
Intervention (Drug)
Empagliflozin low dose bid
Intervention (Drug)
Metformin 1000 mg bid
Intervention (Drug)
Metformin 500 mg bid
Intervention (Drug)
Metformin 1000 mg bid
Intervention (Drug)
Empagliflozin high dose bid
Intervention (Drug)
Metformin 1000 mg bid
Intervention (Drug)
Empagliflozin high dose bid
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01719003
Content hash
76c08d371e5fe0f584304524844563aed91fdbc8582dd85a03b744e23ca4ad21